Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Lamb who wrote (6854)	1/28/1999 5:34:00 PM
From: Anthony Wong	Respond to of 9523

Dow Jones 17:03 T FDA Panel - Pfizer's Tikosyn -2: For Atrial Fibrillation WASHINGTON (Dow Jones)--Pfizer Inc.'s (PFE) heart drug Tikosyn received Federal panel backing Thursday. The panel recommended that the U.S. Food and Drug Administration approve the drug for patients with atrial fibrillation. The FDA usually heeds the advice of its expert advisory panels when deciding whether to approve products for sale in the U.S. During the day-long meeting, Pfizer presented data from several Tikosyn trials. Pfizer's doctor, Friedrich Tilman, told the panel more than 8,500 total patients were studied. He said 1,100 chronic patients in 79 medical centers participated in Tikosyn trials. Dr. Jeremy Ruskin of Massachusetts General Hospital also presented data for Pfizer. Of the patients treated with Tikosyn, 60% to 70% were able to maintain a normal heartbeat rhythm for a year, he said. The company also said there was no difference in non-cardiac adverse events in patients who received Tikosyn compared to those given an inactive placebo. Atrial fibrillation, the most common abnormal heart rhythm, occurs when the heart's upper chambers quiver instead of beating properly. This is a major risk factor for stroke and has related symptoms such as shortness of breath, light-headedness and fatigue. Atrial fibrillation affects more than 2.2 million people in the U.S. and more than 10 million people worldwide. (MORE) DOW JONES NEWS 01-28-99 05:03 PM